The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Abstract
Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum-etoposide) in treatment-naive patients with ES-SCLC.Methods This randomised, open-label, phase 3 trial was done at 209 sites across 23 countries. Eligible patients were adults with untreated ES-SCLC, with WHO performance status 0 or 1 and measurable disease as per Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were randomly assigned (in a 1:1:1 ratio) to durvalumab plus platinum-etoposide; durvalumab plus tremelimumab plus platinum-etoposide; or platinum-etoposide alone. All drugs were administered intravenously. Platinum-etoposide consisted of etoposide 80-100 mg/m 2 on days 1-3 of each cycle with investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m 2 (administered on day 1 of each cycle). Patients received up to four cycles of platinum-etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks in the immunotherapy groups and up to six cycles of platinum-etoposide every 3 weeks plus prophylactic cranial irradiation (investigator's discretion) in the platinum-etoposide group. The primary endpoint was overall survival in the intention-to-treat population. We report results for the durvalumab plus platinum-etoposide group versus the platinum-etoposide group from a planned interim analysis. Safety was assessed in all patients who received at least one dose of their assigned study treatment. This study is registered at ClinicalTrials.gov, NCT03043872, and is ongoing.Findings Patients were enrolled between March 27, 2017, and May 29, 2018. 268 patients were allocated to the durvalumab plus platinum-etoposide group and 269 to the platinum-etoposide group. Durvalumab plus platinum-etoposide was associated with a significant improvement in overall survival, with a hazard ratio of 0·73 (95% CI 0·59-0·91; p=0·0047]); median overall survival was 13·0 months (95% CI 11·5-14·8) in the durvalumab plus platinum-etoposide group versus 10·3 months (9·3-11·2) in the platinum-etoposide group, with 34% (26·9-41·0) versus 25% (18·4-31·6) of patients alive at 18 months. Any-cause adverse events of grade 3 or 4 occurred in 163 (62%) of 265 treated patients in the durvalumab plus platinum-etoposide group and 166 (62%) of 266 in the platinum-etoposide group; adverse events leading to death occurred in 13 (5%) and 15 (6%) patients.Interpretation First-line durvalumab plus platinum-etoposide significantly improved overall survival in patients with ES-SCLC versus a clinically relevant control group. Safety findings were consistent with the known safety profiles of all drugs received.Funding AstraZeneca.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical benefi t with maintenance ICT in specifi c settings was demonstrated in patients with nonsmall cell lung cancer (NSCLC; ref.50 ), extensive-stage small cell lung cancer ( 51,52 ), and bladder cancer ( 53 ), leading to FDA approvals in these tumor types.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [52]
In the citing paper
“Recently, the US FDA‐approved PD‐L1 inhibitors atezolizumab and durvalumab were combined with carboplatin plus etoposide (CP/ET) to target and kill aggressively growing tumors in advanced SCLC patients and reported an overall increase in survival [345, 346].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [346]
In the citing paper
“Moreover, based on the results of CASPIAN, durvalumab combined with platinum plus etoposide therapy was approved for SCLC in the US [69].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [69]
Citations
Cites
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Self-citationFirst-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Self-citationOverall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Self-citationGaron, E. B., Hellmann, M. D., Rizvi, N. A., Carcereny, E., Leighl, N. B., Ahn, M.-J., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00934 · Cited by 1,163
Self-citationProphylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
Slotman, B., Faivre-Finn, C., Kramer, G., Rankin, E., Snee, M., Hatton, M., Postmus, P., Collette, L., Musat, E., & Senan, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071780 · Cited by 1,133
Small cell lung cancer: Where do we go from here?
Byers, L. A., & Rudin, C. M. (2015) · Cancer · doi:10.1002/cncr.29098 · Cited by 636
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Sosman, J. A., Atkins, M. B., Leming, P. D., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2187 · Cited by 619
Self-citationFrüh, M., De Ruysscher, D., Popat, S., Crinò, L., Peters, S., & Felip, E. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt178 · Cited by 613
Rossi, A., Di Maio, M., Chiodini, P., Rudd, R. M., Okamoto, H., Skarlos, D. V., Früh, M., Qian, W., Tamura, T., Samantas, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4905 · Cited by 570
Takahashi, T., Yamanaka, T., Seto, T., Harada, H., Nokihara, H., Saka, H., Nishio, M., Kaneda, H., Takayama, K., Ishimoto, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30230-9 · Cited by 549
Self-citation
Cited by
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Sun, J.-M., Shen, L., Shah, M. A., Enzinger, P., Adenis, A., Doi, T., Kojima, T., Metges, J.-P., Li, Z., Kim, S.-B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01234-4 · Cited by 1,635
Self-citationPD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
“Moreover, based on the results of CASPIAN, durvalumab combined with platinum plus etoposide therapy was approved for SCLC in the US [69].”
Background
Metadata
- Authors
- Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., Voitko, O., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L., Bondarenko, I., Kazarnowicz, A., Losonczy, G., Conev, N. V., Armstrong, J., Byrne, N., Shire, N., Jiang, H., Goldman, J. W., Batagelj, E., Casarini, I., Pastor, A. V., Sena, S. N., Zarba, J. J., Burghuber, O., Hartl, S., Hochmair, M. J., Lamprecht, B., Studnicka, M., Alberto Schlittler, L., Augusto Martinelli de Oliveira, F., Calabrich, A., Colagiovanni Girotto, G., Dos Reis, P., Fausto Nino Gorini, C., Rafael Martins De Marchi, P., Serodio da Rocha Baldotto, C., Sette, C., Zukin, M., Conev, N. V., Dudov, A., Ilieva, R., Koynov, K., Krasteva, R., Tonev, I., Valev, S., Venkova, V., Bi, M., Chen, C., Chen, Y., Chen, Z., Fang, J., Feng, J., Han, Z., Hu, J., Hu, Y., Li, W., Liang, Z., Lin, Z., Ma, R., Ma, S., Nan, K., Shu, Y., Wang, K., Wang, M., Wu, G., Yang, N., Yang, Z., Zhang, H., Zhang, W., Zhao, J., Zhao, Y., Zhou, C., Zhou, J., Zhou, X., Havel, L., Kolek, V., Koubkova, L., Roubec, J., Skrickova, J., Zemanova, M., Chouaid, C., Hilgers, W., Lena, H., Moro-Sibilot, D., Robinet, G., Souquet, P.-J., Alt, J., Bischoff, H., Grohe, C., Laack, E., Lang, S., Panse, J., Reinmuth, N., Schulz, C., Bogos, K., Csánky, E., Fülöp, A., Horváth, Z., Kósa, J., Laczó, I., Losonczy, G., Pajkos, G., Pápai, Z., Pápai Székely, Z., Sárosi, V., Somfay, A., Somogyiné Ezer, É., Telekes, A., Bar, J., Gottfried, M., Heching, N. I., Zer Kuch, A., Bartolucci, R., Bettini, A. C., Delmonte, A., Garassino, M. C., Minelli, M., Roila, F., Verderame, F., Atagi, S., Azuma, K., Goto, H., Goto, K., Hara, Y., Hayashi, H., Hida, T., Hotta, K., Kanazawa, K., Kanda, S., Kim, Y. H., Kuyama, S., Maeda, T., Morise, M., Nakahara, Y., Nishio, M., Nogami, N., Okamoto, I., Saito, H., Shinoda, M., Umemura, S., Yoshida, T., Claessens, N., Cornelissen, R., Heniks, L., Hiltermann, J., Smit, E., Staal van den Brekel, A., Kazarnowicz, A., Kowalski, D., Mańdziuk, S., Mróz, R., Wojtukiewicz, M., Ciuleanu, T., Ganea, D., Ungureanu, A., Dvorkin, M., Luft, A., Moiseenko, V., Poltoratskiy, A., Sakaeva, D., Smolin, A., Statsenko, G., Vasilyev, A., Vladimirova, L., Anasina, I., Chovanec, J., Demo, P., Godal, R., Kasan, P., Stresko, M., Urda, M., Cho, E. K., Ji, J. H., Kim, J.-H., Kim, S.-W., Lee, G.-W., Lee, J.-S., Lee, K. H., Lee, K. H., Lee, Y. G., Amelia Insa Molla, M., Domine Gomez, M., Ignacio Delgado Mingorance, J., Isla Casado, D., Lopez Brea, M., Majem Tarruella, M., Morán Bueno, T., Navarro Mendivil, A., Paz-Ares Rodríguez, L., Ponce Aix, S., Rosario Garcia Campelo, M., Chang, G.-C., Chen, Y.-H., Chiu, C.-H., Hsia, T.-C., Lee, K.-Y., Li, C.-T., Wang, C.-C., Wei, Y.-F., Wu, S.-Y., Alacacıoğlu, A., Çiçin, I., Demirkazik, A., Erman, M., Göksel, T., Özgüroğlu, M., Adamchuk, H., Bondarenko, I., Kolesnik, O., Kryzhanivska, A., Ostapenko, Y., Shevnia, S., Shparyk, Y., Trukhin, D., Ursol, G., Voitko, N., Voitko, O., Vynnychenko, I., Babu, S., Chen, Y., Chiang, A., Chua, W., Dakhil, S., Dowlati, A., Goldman, J. W., Haque, B., Jamil, R., Knoble, J., Lakhanpal, S., Mi, K., Nikolinakos, P., Powell, S., Ross, H., Schaefer, E., Schneider, J., Spahr, J., Spigel, D., Stilwill, J., Sumey, C., & Williamson, M.
- Affiliations
- Universidad Complutense de Madrid (ES)
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (United States) (US)
- University of California, Los Angeles (US)
- Samsung Changwon Hospital (KR)
- Okayama University Hospital (JP)
- Asklepios Fachkliniken München-Gauting (DE)
- Dnipro State Medical University (UA)
- Istanbul University-Cerrahpaşa (TR)
- Kyiv City Clinical Oncology Center (UA)
- Corresponding author
- Paz-Ares, Luis
- ORCID
- Paz-Ares, Luis
- Ponce, Santiago
- Armstrong, Jon
- Shire, Norah
- Jiang, Haiyi
- Casarini, Ignacio
- Sena, Susana Noemi
- Burghuber, Otto
- Hartl, Sylvia
- Lamprecht, Bernd
- Studnicka, Michael
- Calabrich, Aknar
- Zukin, Mauro
- Dudov, Assen
- Koynov, Krassimir
- Tonev, Ivan
- Bi, Minghong
- Chen, Chengshui
- Chen, Yuan
- Chen, Zhendong
- Fang, Jian
- Feng, Jifeng
- Han, Zhigang
- Hu, Jie
- Hu, Yi
- Liang, Zongan
- Ma, Rui
- Nan, Kejun
- Shu, Yongqian
- Wang, Kai
- Wang, Mengzhao
- Wu, Gang
- Yang, Nong
- Yang, Zhixiong
- Zhang, Helong
- Zhang, Wei
- Zhao, Jun
- Zhao, Yanqiu
- Zhou, Caicun
- Zhou, Jianying
- Zhou, Xiangdong
- Chouaid, Christos
- Hilgers, Werner
- Bischoff, Helge
- Lang, Susanne
- Panse, Jens
- Bogos, Krisztina
- Csánky, Eszter
- Horváth, Zsolt
- Laczó, Ibolya
- Pápai, Zsuzsanna
- Bar, Jair
- Delmonte, Angelo
- Garassino, Marina Chiara
- Azuma, Koichi
- Hara, Yu
- Hayashi, Hidetoshi
- Hida, Toyoaki
- Kanda, Shintaro
- Kim, Young Hak
- Kuyama, Shoichi
- Morise, Masahiro
- Nakahara, Yasuharu
- Nishio, Makoto
- Nogami, Naoyuki
- Okamoto, Isamu
- Saito, Haruhiro
- Umemura, Shigeki
- Yoshida, Tatsuya
- Cornelissen, Robin
- Smit, Egbert
- Kowalski, Dariusz
- Mróz, Robert
- Wojtukiewicz, Marek
- Ciuleanu, Tudor
- Sakaeva, Dina
- Smolin, Alexey
- Urda, Michal
- Kim, Joo-Hang
- Kim, Sang-We
- Lee, Gyeong-Won
- Lee, Jong-Seok
- Lee, Ki Hyeong
- Lee, Kyung Hee
- Chang, Gee-Chen
- Chiu, Chao-Hua
- Hsia, Te-Chun
- Lee, Kang-Yun
- Wang, Chin-Chou
- Wu, Shang-Yin
- Alacacıoğlu, Ahmet
- Erman, Mustafa
- Göksel, Tuncay
- Kolesnik, Oleksii
- Kryzhanivska, Anna
- Shparyk, Yaroslav
- Vynnychenko, Ihor
- Babu, Sunil
- Chiang, Anne
- Dakhil, Shaker
- Dowlati, Afshin
- Powell, Steven
- Ross, Helen
- Schaefer, Eric
- Spigel, David
- Sumey, Christopher
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 394
- Issue
- 10212
- Pages
- 1929-1939
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2977392388
- Cited by
- 2,298
- References
- 29
- Citations by year
- 2026: 308 · 2025: 379 · 2024: 353 · 2023: 358 · 2022: 334 · 2021: 348 · 2020: 209 · 2019: 4
- FWCI
- 93.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- extensive-stage small cell lung cancer, durvalumab, tremelimumab, platinum-etoposide chemotherapy, first-line therapy, immune checkpoint inhibitors, overall survival, maintenance immunotherapy, prophylactic cranial irradiation, CASPIAN trial, treatment safety, immune-related adverse events, carboplatin, cisplatin
- MeSH terms
- Antineoplastic Agents, Immunological, Progression-Free Survival, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Phytogenic, Cisplatin, Drug Administration Schedule, Etoposide, Female, Humans, Lung Neoplasms, Male, Middle Aged, Carboplatin, Small Cell Lung Carcinoma, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)32222-6
- The paper
- Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., Voitko, O., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L., Bondarenko, I., Kazarnowicz, A., Losonczy, G., Conev, N. V., . . . Williamson, M. (2019). Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)32222-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.